Treace Medical Concepts, Inc. (NASDAQ:TMCI) Director James T. Treace Sells 10,000 Shares

James T. Treace, the director of the company, sold 10,000 shares in a transaction on May 1, 2008. Stock was sold for $25.24 on average, a value of $252,400.00. After the sale was completed, the director owns 861.441 shares valued at $21,742,770.84. The SEC website
.

Treace Medical Concepts stock down 5.4 %

During trading hours, the stock price fell $1.40 to $24.63, a decrease of $1.40. Stock of the company traded at 215,807 shares compared to an average of 395,630. The company's debt-to equity ratio is 0.87. Its current ratio is 4.41, and its quick ratio is 3.77. The company's market cap is $1.51 billion. It has a price to earnings ratio of -31.9 and a beta value of -0.01. Treace Medical Concepts Inc.'s low for the past year was $12.48, and its high is $27.97. The company released its last quarterly earnings report on March 7th. The company's ($0.08) earnings-per-share (EPS) for quarter surpassed the consensus estimate ($0.13) by $0.05. Revenue for the company was $49.77 millions during the quarter. Treace Medical Concepts posted a negative return of equity of 54.51%, and a net margin of negative 30.19%. Analysts predict Treace Medical Concepts, Inc. to post a -0.8 EPS in the current year.

Wall Street analysts forecast growth

TMCI was the subject of a few recent research reports. Truist Financial began covering Treace Medical Concepts on Monday in a research note. They gave the company a rating of 'buy' and set a price target of $33.00. Stephens initiated coverage on Treace Medical Concepts shares in a research note on Monday, April 10. The company was given an 'equal-weight' rating with a price target of $26.00. Morgan Stanley raised their price target for Treace Medical Concepts shares from $28.00 up to $30.00 in a research note on March 8th. The stock was also given an 'overweight rating'. BTIG Research raised their price target for Treace Medical Concepts shares from $29.00 up to $32.00 in a report published on Monday, April 17. Four analysts have given the company a buy rating, while one analyst gave it a hold. According to MarketBeat data, the average rating for the stock is 'Moderate Buyer' with an average price target of $29.60.

Institutional Inflows & Outflows

TMCI has seen a number of hedge fund positions change recently. Altshuler Shaham Ltd purchased a new position of shares in Treace Medical Concepts valued at approximately $25,000 during the fourth quarter. UBS Group AG increased its holdings of Treace Medical Concepts from 79.1% to $25,000 in the third quarter. UBS Group AG owns now 1,442 shares worth $32,000, after adding 637 more shares. MCF Advisors LLC purchased a new Treace Medical Concepts position worth $45,000 in the third quarter. Van ECK Associates Corp purchased a new Treace Medical Concepts position in the fourth quarter for $52,000. TD Capital Management LLC also bought a position in Treace medical Concepts during the fourth quarter, worth $57,000. The company's shares are owned by institutional investors and hedge fund managers, who own 46.17 percent.

About Treace Medical Concepts

Get Rating
)

Treace Medical Concepts Inc is an orthopedic medical device manufacturer that designs, manufactures and markets medical devices to foot and ankle surgeons across the United States. It offers the Lapiplasty, a procedure that allows podiatric doctors to treat all three dimensions in the bunions. This provides patients with both a cosmetic and a medical improvement.

MarketBeat.com offers a FREE daily email newsletter
.